RDY — Dr Reddy's Laboratories Share Price
Last trade - 00:00- $12.13bn
- $11.42bn
- IN₹246.70bn
- 99
- 35
- 82
- 83
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.14 | ||
| PEG Ratio (f) | 4.09 | ||
| EPS Growth (f) | 4.64% | ||
| Dividend Yield (f) | 0.69% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.97 | ||
| Price to Tang. Book | 4.77 | ||
| Price to Free Cashflow | 20.61 | ||
| Price to Sales | 3.72 | ||
| EV to EBITDA | 12.42 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 23.72% | ||
| Return on Equity | 22.6% | ||
| Operating Margin | 23.02% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 154,482 | 175,170 | 190,475 | 215,452 | 246,697 | 275,683.09 | 293,974.72 | 11.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +72.8 | +68.06 | -23.93 | +16.27 | +68.39 | +12.49 | +4.64 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).
Directors
- Satish Reddy CHM (53)
- G. Prasad CCH (60)
- Erez Israeli CEO (54)
- Parag Agarwal CFO (54)
- Patrick Aghanian CEX (56)
- Marc Kikuchi CEX (52)
- M. Ramana CEX (53)
- Archana Bhaskar CHO (54)
- Mukesh Rathi CIO (46)
- Vivek Mittal CCO
- Raymond De Vre OTH (53)
- Sauri Gudlavalleti OTH (43)
- Anil Namboodiripad OTH (55)
- Deepak Sapra OTH (46)
- Sanjay Sharma OTH (53)
- P. Yugandhar OTH (50)
- K. Krishnan IND (62)
- Penny Wan IND
- Bruce Carter NID (78)
- Bharat Doshi NID (72)
- Sridar Iyengar NID (68)
- Prasad Menon NID (75)
- Kalpana Morparia NID (72)
- Allan Oberman NID (63)
- Leo Puri NID (60)
- Shikha Sharma NID (62)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 24th, 1984
- Public Since
- January 1st, 1986
- No. of Shareholders
- 239,005
- No. of Employees
- 24,832
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 166,522,232
- Address
- 8-2-337, Road No.3 Banjara Hills, HYDERABAD, 500034
- Web
- https://www.drreddys.com/
- Phone
- +91 4049002900
- Contact
- Amit Agarwal
- Auditors
- S.R. BATLIBOI & ASSOCIATES LLP
Upcoming Events for RDY
Similar to RDY
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
As of Today at 19:24 UTC, shares in Dr Reddy's Laboratories are trading at $71.42. This share price information is delayed by 15 minutes.
Shares in Dr Reddy's Laboratories last closed at $71.42 and the price had moved by +18.48% over the past 365 days. In terms of relative price strength the Dr Reddy's Laboratories share price has underperformed the S&P500 Index by -4.32% over the past year.
The overall consensus recommendation for Dr Reddy's Laboratories is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Dr Reddy's Laboratories dividend yield is 0.67% based on the trailing twelve month period.
Last year, Dr Reddy's Laboratories paid a total dividend of IN₹40.00, and it currently has a trailing dividend yield of 0.67%. We do not have any data on when Dr Reddy's Laboratories is to next pay dividends.
We do not have data on when Dr Reddy's Laboratories is to next pay dividends. The historic dividend yield on Dr Reddy's Laboratories shares is currently 0.67%.
To buy shares in Dr Reddy's Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $71.42, shares in Dr Reddy's Laboratories had a market capitalisation of $12.13bn.
Here are the trading details for Dr Reddy's Laboratories:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: RDY
Based on an overall assessment of its quality, value and momentum Dr Reddy's Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Dr Reddy's Laboratories is $78.15. That is 9.42% above the last closing price of $71.42.
Analysts covering Dr Reddy's Laboratories currently have a consensus Earnings Per Share (EPS) forecast of IN₹314.34 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dr Reddy's Laboratories. Over the past six months, its share price has underperformed the S&P500 Index by -8.22%.
As of the last closing price of $71.42, shares in Dr Reddy's Laboratories were trading +3.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dr Reddy's Laboratories PE ratio based on its reported earnings over the past 12 months is 18.14. The shares last closed at $71.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dr Reddy's Laboratories' management team is headed by:
- Satish Reddy - CHM
- G. Prasad - CCH
- Erez Israeli - CEO
- Parag Agarwal - CFO
- Patrick Aghanian - CEX
- Marc Kikuchi - CEX
- M. Ramana - CEX
- Archana Bhaskar - CHO
- Mukesh Rathi - CIO
- Vivek Mittal - CCO
- Raymond De Vre - OTH
- Sauri Gudlavalleti - OTH
- Anil Namboodiripad - OTH
- Deepak Sapra - OTH
- Sanjay Sharma - OTH
- P. Yugandhar - OTH
- K. Krishnan - IND
- Penny Wan - IND
- Bruce Carter - NID
- Bharat Doshi - NID
- Sridar Iyengar - NID
- Prasad Menon - NID
- Kalpana Morparia - NID
- Allan Oberman - NID
- Leo Puri - NID
- Shikha Sharma - NID